(Q37204150)

18 August 2017

1 reference

title

Therapeutic alternatives for chronic urticaria: an evidence-based review, Part 2. (English)

1 reference

18 August 2017

1 reference

1 reference

Matt Morgan

1

1 reference

18 August 2017

David A Khan

series ordinal

2

1 reference

18 August 2017

publication date

1 June 2008

1 reference

Annals of Allergy, Asthma & Immunology

18 August 2017

published in

1 reference

18 August 2017

volume

100

1 reference

18 August 2017

issue

6

1 reference

18 August 2017

page(s)

517-26; quiz 526-8, 544

1 reference

Clinical guidelines: developing guidelines

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

A Comparison of Plasma Protein Changes Induced by Danazol, Pregnancy, and Estrogens*

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Immunosuppressive effects of danazol in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Beneficial effects of danazol on symptoms and laboratory changes in cholinergic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Cholinergic pruritus, erythema and urticaria: a disease spectrum responding to danazol

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Aquagenic urticaria and human immunodeficiency virus infection: treatment with stanozolol

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

The treatment of glucocorticosteroid-dependent chronic urticaria with stanozolol

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Stanozolol in chronic urticaria: a double blind, placebo controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

The effect of methotrexate and hydroxyurea on neutrophil chemotaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Molecular action of methotrexate in inflammatory diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Methotrexate in corticosteroid-resistant urticaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Methotrexate-responsive chronic idiopathic urticaria: a report of two cases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Methotrexate-induced exacerbation of urticarial vasculitis: an unusual adverse reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Immunomodulatory action of intravenous immunoglobulin.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Intravenous immunoglobulin in autoimmune chronic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

The effectiveness of low-dose intravenous immunoglobulin in chronic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Autoimmune urticaria response to high-dose intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Are IVIG for chronic unremitting urticaria effective?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Effect of high-dose intravenous immunoglobulin in delayed pressure urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Treatment of solar urticaria by intravenous immunoglobulins and PUVA therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

[Hypocomplementemic urticarial vasculitis syndrome. Successful therapy with intravenous immunoglobulins]

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Indications and action mechanisms of phototherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Solar urticaria: treatment with PUVA and mediator inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

PUVA-treatment for solar urticaria and persistent light reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Successful treatment of solar urticaria by extracorporeal photochemotherapy (photopheresis)--a case report

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

A case of chronic urticaria and vitiligo, associated with thyroiditis, treated with PUVA

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Treatment of chronic urticaria with PUVA or UVA plus placebo: a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Narrow-band (TL-01) ultraviolet B phototherapy for chronic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Urticaria and fibrinolysis*

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Treatment of chronic urticaria with a proteinase (kallikrein) inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Tranexamic acid in chronic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Inhibitory effect of heparin on skin reactivity to autologous serum in chronic idiopathic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Chronic urticaria with angio-oedema controlled by warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Warfarin sodium therapy for chronic urticaria and angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Warfarin treatment of chronic idiopathic urticaria and angio-oedema.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Warfarin in the treatment of chronic urticaria/angio-edema

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Chronic urticaria responding to subcutaneous heparin sodium

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Hypocomplementaemic urticarial vasculitis: successful treatment with cyclophosphamide-dexamethasone pulse therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaemic urticarial vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Successful treatment of autoimmune chronic idiopathic urticaria with intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Oral cyclophosphamide in a case of cyclosporin and steroid-resistant chronic urticaria showing autoreactivity on autologous serum skin testing

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Sustained dapsone-induced remission of hypocomplementemic urticarial vasculitis--a case report.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Identification and functional characterization of voltage-dependent calcium channels in T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Inhibition of histamine release from dispersed human lung and tonsillar mast cells by nicardipine and nifedipine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Angioedematous urticaria in a diabetic patient successfully treated with nifedipine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Calcium channel blocking agents in the treatment of urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Calcium antagonist in the treatment of symptomatic dermographism. Low-dose and high-dose studies with nifedipine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Therapy of chronic idiopathic urticaria with nifedipine: demonstration of beneficial effect in a double-blinded, placebo-controlled, crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Gold therapy and its indications in dermatology. A review

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Urticarial vasculitis--response to gold therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Therapeutic plasmapheresis and plasma exchange

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Plasmapheresis in solar urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Solar urticaria: treatment by plasmapheresis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Combined treatment of solar urticaria with plasmapheresis and PUVA

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Plasmapheresis for severe, unremitting, chronic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Effects of orally administered sodium cromoglycate in asthma and urticaria due to foods

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Oral sodium cromoglycate in chronic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Effect in man of oral terbutaline on cutaneous reactions induced by allergen and cold stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Treatment of chronic urticaria with a beta2-adrenergic stimulant

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Terbutaline and ketotifen in cold urticaria in a child.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

A controlled trial of therapy in chronic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Theophylline as 'add-on' therapy to cetirizine in patients with chronic idiopathic urticaria. A randomized, double-blind, placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Treatment of cold urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Delayed pressure urticaria. Clinical features, laboratory investigations, and response to therapy of 44 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

A possible role for cyclooxygenase 2 inhibitors in the treatment of chronic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Interferon treatment of patients with chronic urticaria and mastocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Interferon therapy for chronic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Autologous Whole Blood Injections to Patients with Chronic Urticaria and a Positive Autologous Serum Skin Test: A Placebo-Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Urticaria successfully treated by desensitization with grass pollen extract

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Successful treatment of delayed pressure urticaria with anti-TNF-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Non‐complementaemic urticarial vasculitis: successful treatment with the IL‐1 receptor antagonist, anakinra

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

Lack of response of severe steroid-dependent chronic urticaria to rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

The vexing urticaria problem: present concepts of etiology and management

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960047-6

7 January 2021

10.1016/S1081-1206(10)60047-6

Identifiers

DOI

1 reference

18 August 2017

1 reference